Harry Lee, MD
Allergy & Immunology · Montgomery, ALNPI 1225029259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 482 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 25.5% of the total.
Across 482 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Genentech USA, Inc.$1K
- CSL Behring$1K
- Regeneron Healthcare Solutions, Inc.$760
- Sanofi$478
- plus $3K from 24 others
What the payments were for
- Consulting fees$310%
- Food & beverage$10,18197%
- Education$2863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $2,673 |
| GSK | 109 | $1,748 |
| Genentech USA, Inc. | 44 | $1,123 |
| CSL Behring | 40 | $1,101 |
| Regeneron Healthcare Solutions, Inc. | 30 | $760 |
| Sanofi | 17 | $478 |
| Novartis | 18 | $417 |
| Amgen(2 entities) | 13 | $293 |
| Octapharma USA, Inc. | 13 | $291 |
| Teva Pharmaceuticals USA, Inc. | 17 | $243 |
| Pfizer | 13 | $231 |
| Pharming Healthcare, Inc. | 6 | $147 |
| Alk-abello, Inc | 5 | $122 |
| Aimmune Therapeutics, Inc. | 4 | $105 |
| ADMA Biomanufacturing LLC | 4 | $100 |
| Kaleo, Inc. | 4 | $84 |
| Optinose US, Inc. | 5 | $69 |
| Grifols USA, LLC | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Biocryst US Sales Co., LLC | 3 | $51 |
| Genentech, Inc. | 1 | $50 |
| Dermavant Sciences, Inc. | 2 | $44 |
| Merck | 2 | $41 |
| Boehringer Ingelheim | 3 | $41 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Jubilant Hollisterstier LLC | 1 | $23 |
| Medtronic | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,497 in reported general payments places this provider in the 60th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 28 | $105,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $73,718 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,974 |
| Zafirlukast | 59 | $13,284 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,972 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,692 |
| Azelastine Hcl | 57 | $2,060 |
| Famotidine | 81 | $1,686 |
| Cimetidine | 14 | $1,432 |
| Montelukast Sodium | 79 | $1,227 |
| Theophylline ErTheophylline Anhydrous | 27 | $968 |
| Doxycycline Hyclate | 24 | $965 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $841 |
| Levocetirizine Dihydrochloride | 45 | $698 |
| Ventolin HfaAlbuterol Sulfate | 12 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,748 | $92,384159 claims |
| AstraZenecaSymbicort | $2,673 | $2,97213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Montgomery
- David FrazerMontgomery$8K
- David FrazerMontgomery$241
- Margaret JakesMontgomery$204
- John AndersonHomewood$789K
- Joseph ForesterCullman$719K
- William DavidsonDaphne$98K
- Thomas ScottBessemer$61K
- Thomas AtkinsonBirmingham$53K
- Njeri MainaBirmingham$44K
- Michael PolcariBirmingham$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.